Discovery of an Isothiazolinone-Containing Antitubercular Natural Product Levesquamide.
Levesquamide shows promising antimicrobial activity against Mycobacterium tuberculosis with no observed cytotoxicity in Vero cells, but further research is needed to assess its clinical relevance.
Where it sits
this study against the rest of the pe 22-28 corpusSummary and findings
Levesquamide is a new polyketide-nonribosomal peptide hybrid isolated from Streptomyces sp. RKND-216. It exhibited antimicrobial activity against Mycobacterium tuberculosis H37Rv with MIC values of 9.65 μM and 22.28 μM in different assays. No cytotoxicity was observed against the Vero cell line.
Abstract
Antitubercular agent levesquamide is a new polyketide-nonribosomal peptide (PK-NRP) hybrid marine natural product isolated from <i>Streptomyces</i> sp. RKND-216. The structure contains a rare isothiazolinone moiety which has only been reported in collismycin SN. Structure elucidation by NMR spectroscopy was a significant challenge due to a deficiency of protons in this aromatic moiety. Therefore, the genome of <i>Streptomyces</i> sp. RKND-216 was sequenced to identify the levesquamide biosynthetic gene cluster (BGC). Analysis of the BGC provided structural insights and guided stable-isotope labeling experiments, which led to the assignment of the fused pyridine-isothiazolinone moiety. The BGC and the labeling experiments provide further insights into the biosynthetic origin of isothiazolinones. Levesquamide exhibited antimicrobial activity in the microplate alamarBlue assay (MABA) and low oxygen recovery assay (LORA) against <i>Mycobacterium tuberculosis</i> H37Rv with minimum inhibitory concentration (MIC) values of 9.65 and 22.28 μM, respectively. Similar activity was exhibited against rifampicin- and isoniazid-resistant <i>M. tuberculosis</i> strains with MIC values of 9.46 and 9.90 μM, respectively. This result suggests levesquamide has a different mode of action against <i>M. tuberculosis</i> compared to the two first-line antitubercular drugs rifampicin and isoniazid. Furthermore, levesquamide shows no cytotoxicity against the Vero cell line, suggesting it may have a useful therapeutic window.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.